Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Bruins Live

1

0

1st Prd 12:30

Around the Region

Biogen’s Hemophilia drug awaits approval

Biogen Idec Inc., the Weston biotechnology company known for its drugs to treat multiple sclerosis drugs, is seeking US regulatory approval for a long-lasting treatment for hemophilia A, a rare inherited disorder that impairs blood clotting.

Current treatments can require a patient to get three or four injections a week. Biogen Idec’s hope is that a patient would need one or two injections per week.

Continue reading below

If approved, the treatment would be the first major advance­ for hemophilia A patients­ in more than two decades, the company said.

In a press release, the company said it is seeking Food and Drug Administration approval to the market recombinant factor VIII Fc fusion protein (rFVIIIFc) for the treatment of hemophilia A.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week